Natural Product (NP) Details
General Information of the NP (ID: NP8392) | |||||
---|---|---|---|---|---|
Name |
Pseudoephedrine
|
||||
Synonyms |
PSEUDOEPHEDRINE; (+)-Pseudoephedrine; d-Pseudoephedrine; Isoephedrine; Sudafed; trans-Ephedrine; d-Isoephedrine; Psi-ephedrin; Psi-ephedrine; d-psi-Ephedrine; L(+)-psi-Ephedrine; (+)-threo-Ephedrine; L-(+)-Pseudoephedrine; (+)-psi-Ephedrine; 90-82-4; Pseudoefedrina; Pseudoephedrinum; Besan; (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol; (+)-(1S,2S)-Pseudoephedrine; Pseudoephedrine d-form; (1S,2S)-Pseudoephedrine; (1S,2S)-(+)-Pseudoephedrine; d-psi-2-Methylamino-1-phenyl-1-propanol; UNII-7CUC9DDI9F; 7CUC9DDI9F; 90-82-4 (free base); Pseudoephedrine, (+)-; CHEBI:51209; Pseudoephedrine, L-(+)-; alpha-(1-(Methylamino)ethyl)benzyl alcohol; Pseudoephedrine (D); Pseudoefedrina [INN-Spanish]; Pseudoephedrinum [INN-Latin]; (+) threo-2-(methylamino)-1-phenyl-1-propanol; Pseudoephedrine [INN:BAN]; Pseudoephedrine Ephedrine; psi-Ephedrine, (+)-; 2-(Methylamino)-1-phenyl-1-propanol; Neodurasina (TN); Acunaso (TN); pseudophedrine sulphate; HSDB 3177; Pseudoephedrine (INN); Pseudoephedrine polistirex; EINECS 202-018-6; Benzenemethanol, .alpha.-[(1S)-1-(methylamino)ethyl]-, (.alpha.S)-; (I)-Ephedrin; ephedrine-(racemic); (+) pseudoephedrine; d-Pseudoephedrine base; Spectrum_000878; Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))-; Spectrum2_001303; Spectrum3_001771; Spectrum4_001162; Spectrum5_000650; Lopac-E-3250; (1S,2S) pseudoephedrine; (1S,2S)-2-methylamino-1-phenylpropan-1-ol; (1s, 2s) pseudoephedrine; EC 202-018-6; SCHEMBL4368; CHEMBL1590; (1S,2S)-2-(methylamino)-1-phenyl-propan-1-ol; BSPBio_003261; KBioGR_001763; KBioSS_001358; BIDD:GT0817; DivK1c_000451; SPBio_001365; GTPL7286; DTXSID0023537; KBio1_000451; KBio2_001358; KBio2_003926; KBio2_006494; KBio3_002762; ZINC20259; (1s, 2s)-(+)-pseudoephedrine; NINDS_000451; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alphaS)-; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)-; PDSP1_001347; AKOS025401512; DB00852; MCULE-5756045923; IDI1_000451; (1S,2S)-(+)-Pseudoephedrine, 98%; NCGC00015408-01; NCGC00178180-01; NCI60_002955; SBI-0051498.P003; C02765; D08449; 064P256; Q263958; BRD-K84175871-003-02-2; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)- (9CI); (S,S)-(+)-Pseudoephedrine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
Click to Show/Hide
|
||||
Species Origin | Ephedra altissima ... | Click to Show/Hide | |||
Ephedra altissima | |||||
Disease | Breathing abnormality [ICD-11: MD11] | Approved | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C10H15NO
|
||||
PubChem CID | |||||
Canonical SMILES |
CC(C(C1=CC=CC=C1)O)NC
|
||||
InChI |
1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1
|
||||
InChIKey |
KWGRBVOPPLSCSI-WCBMZHEXSA-N
|
||||
CAS Number |
CAS 90-82-4
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Domperidone | Digestive system disease | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Experimental
Result(s) |
The combination of domperidone and pseudoephedrine improved self reported snoring and sleepiness, and may have improved apneic episodes and sleep-related nocturnal oxygen desaturation in patients with obstructive sleep apnea provided the proportion of time spent asleep did not diminish. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Dopamine D2 receptor (D2R) | Molecule Info | [3] | |
KEGG Pathway | Rap1 signaling pathway | Click to Show/Hide | ||
2 | cAMP signaling pathway | |||
3 | Neuroactive ligand-receptor interaction | |||
4 | Gap junction | |||
5 | Dopaminergic synapse | |||
6 | Parkinson's disease | |||
7 | Cocaine addiction | |||
8 | Alcoholism | |||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | Click to Show/Hide | ||
2 | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||
3 | Dopamine receptor mediated signaling pathway | |||
4 | Nicotine pharmacodynamics pathway | |||
Reactome | Dopamine receptors | Click to Show/Hide | ||
2 | G alpha (i) signalling events | |||
WikiPathways | Hypothetical Network for Drug Addiction | Click to Show/Hide | ||
2 | Monoamine GPCRs | |||
3 | GPCRs, Class A Rhodopsin-like | |||
4 | Genes and (Common) Pathways Underlying Drug Addiction | |||
5 | GPCR ligand binding | |||
6 | GPCR downstream signaling | |||
7 | Nicotine Activity on Dopaminergic Neurons |
